2019年CNS《成人脑转移瘤新型及试验性疗法的循证指南》解读  

Interpretation of Evidence-based Guidelines on Role of Emerging and Investigational Therapies for Treatment of Adults with Metastatic Brain Tumors Published by CNS in 2019

作　　者：汤韫钰 范存刚[1] 刘如恩[1] TANG Yunyu;FAN Cungang;LIU Ruen(Department of Neurosurgery,Peking University People’s Hospital,Beijing 100044,China)

机构地区：[1]北京大学人民医院神经外科,北京100044

出　　处：《肿瘤防治研究》2020年第2期124-128,共5页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金(81001009);北京大学人民医院研究与发展基金(RDC 2015-05,RDE 2018-07)。

摘　　要：脑转移瘤是成人最常见的颅内肿瘤之一。美国神经外科医师大会(Congress of Neurological Surgeons,CNS)曾于2010年发布《脑转移瘤治疗的循证医学指南》,为脑转移瘤的规范化治疗奠定了基础。基于近年来新型疗法的进展,该学会在原指南基础上,回顾分析最新文献,制定了2019版《成人脑转移瘤治疗中新兴及试验性疗法的系统回顾和循证指南》,对高强度聚焦超声、激光间质热疗、放射增敏、免疫调节、分子靶向药物等新型治疗方法进行了讨论。本文将就新指南作一介绍和解读。Metastatic brain tumors are the most common intracranial tumors among adults.The Congress of Neurological Surgeons(CNS)published Evidence-based Clinical Practice Parameter Guidelines for the Treatment of Patients with Metastatic Brain Tumors in 2010,which set a foundation for standardized treatment of metastatic brain tumors.Based on recent advances in novel and investigational therapies,CNS has established Systematic Review and Evidence-Based Guidelines on the Role of Emerging and Investigational Therapies for the Treatment of Adults with Metastatic Brain Tumors in 2019,focusing on high intensity focused ultrasound,laser interstitial thermal therapy,radiation sensitizers,immune modulators,molecular targeted agents and so on.The guideline is hereby introduced and interpreted.

关 键 词：成人脑转移瘤 放射增敏剂 局部治疗 免疫调节剂 分子靶向药物 

分 类 号：R739.41[医药卫生—肿瘤]